Evidence map›Paper›PMID 40468418›Full record

ArticleCost effectiveness and resource allocation : C/E2025

Cost-effectiveness analysis of a new paradigm to simplify testing, monitoring and treatment of hepatitis C virus in the United States.

Douglas Dietrich, Nancy Reau, Aijaz Ahmed, Rob Blissett, Adam Igloi-Nagy, Alon Yehoshua

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cost effectiveness and resource allocation : C/E, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Douglas DietrichInstitute for Liver Medicine, Mount Sinai Health System, New York, USA.
Nancy ReauDepartment of Hepatology, Rush University Medical Center, Chicago, USA.
Aijaz AhmedDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, USA.
Rob BlissettMaple Health Group, LLC, New York, USA.
Adam Igloi-NagyMaple Health Group, LLC, New York, USA. adam.igloi-nagy@maplehealthgroup.com.
Alon YehoshuaFormerly Gilead Sciences, Foster City, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The hepatitis C virus (HCV) testing and treatment pathway in the United States (US) includes a range of tests and appointments causing delays and loss to follow-up. We assessed the cost-effectiveness of simplifying the pathway using an economic model to estimate health outcomes, cost differences and incremental cost per quality-adjusted life year (QALY) and life year (LY) of the new paradigm compared to the other scenarios. The analysis compared three scenarios, one based on treatment guidelines, one based on real-world practice and a hypothetical scenario with a simplified pathway ("new paradigm"); these differed in testing and treatment process steps and times. The new paradigm resulted in cost reductions between $19,751 and $16,448, and excess QALYs between 0.42 and 0.70, suggesting that simplifying the US HCV patient pathway may be cost-effective and allows a quicker path to successful treatment and reduce the number of patients lost to follow-up.

Indexed as

Cost-utility modelHepatitis C virusTesting and treatmentUnited States

Identifiers

PMID40468418
PMCPMC12135392

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.